Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-03-01

Clinical Trial Update: Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bryostatin-1 in combination with cytarabine for relapsed acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bryostatin-1 (bryostatin-1)
  • CYTARABINE (CYTARABINE)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Leukemia | Phase 2 | Status: COMPLETED